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purposes, prA simple, efficient, and stable high-performance liquid chromatography (HPLC) separation method for a combination
of rifampicin (RIF), its major metabolite 25-O-desacetyl rifampicin (25ODESRIF), and neostigmine (NEO) was devel-
oped and validated. The drugs individually, and in combination, were analyzed using a Waters Alliance 2695 HPLC
coupled with 2996 photodiode array detector (PDA). Successful separation of combined drugs was achieved by gradient
elution on a reverse-phase C-18 Phenomenex Luna column, using a mobile phase consisting of water and methanol at
detection wavelength of 254 nm. The HPLC retention times were consistent at ±7.70 min, ±8.25 min, and ±10.70 min
for RIF, 25ODESRIF, and NEO, respectively. The regression data for the calibration plots exhibited linear relationship
(R2 = 0.995) in the range of 0–200 μM for both RIF and 25ODESRIF, and the lower limit of detection (LLOD) and
lower limit of quantification (LLOQ) were calculated at 5.86 μM and 17.75 μM for RIF and 7.78 μM and 23.57 μM
for 25ODESRIF, respectively. The method was evaluated using in vitro human liver microsomes (HLMs) assays, and
linearity was established for the 15, 30, 45, and 60 min incubations (R2 = 0.99). The formation of 25ODESRIF was char-
acterized by hyperbolic kinetics (Km 48.23 μM, Vmax 1.233 pmol/min/mg protein, and CLint 0.026 μl/min/mg protein).
The method was applied in HLM assays to understand the herb–drug interaction (HDI) potential of Althaea officinalis, a
popular African herb consumed by tuberculosis (TB) patients, with RIF. None of the extracts of A. officinalis inhibited
the esterase-mediated metabolism pathway of RIF, compared to the positive control nelfinavir (IC50 = 9.59 μM). The
method provides a tool for quantifying RIF and 25ODESRIF in in vitro drug metabolism assays as well as investigating
herb– and drug–drug interactions (DDIs).
Keywords: HPLC, C-18, rifampicin, 25-O-desacetyl rifampicin, neostigmine, human liver microsomes, Michaelis–
Menten kinetics, Althaea officinalis, herb–drug interactionIntroduction
Rifampicin (RIF) (3-[4-methyl piperazinyl-iminomethyl] rifa-
mycin SV; rifampin) is a first-line antibiotic along with isonia-
zid (INH), pyrazinamide (PYR), ethambutol (ETB), and
streptomycin (STP) in the treatment of pulmonary and extrapul-
monary tuberculosis (TB) and has a unique role in the killing of
semi-dormant tubercle bacilli (Mycobacterium tuberculosis) [1].
The World Health Organization recommends a 6-month reg-
imen comprising RIF, INH, PYR, and ETB which are given
together for the first 2 months followed by RIF and INH ther-
apy for the next 4 months. RIF is mainly eliminated in the bile
and then reabsorbed; hence, enterohepatic circulation ensues.
The drug is deacylated into its microbiologically active metab-
olite 25-O-desacetyl rifampicin (25ODESRIF), by esterases or
by enzymes present in microsomal cells [2]. 25ODESRIF is
less absorbable as compared to the parent drug [3].
RIF is used as an inducer of cytochrome P450 3A4 (CYP 3A4)
to analyze the effect of herbal medicine on the activity of this en-
zyme [4, 5]. It induces gut and liver (hepatic) CYP3A4 and auto-
induces its own metabolism [6]. P-glycoprotein (P-gp), along
with B-esterases, is involved in disposition of rifampicin [7].
Very few high-performance liquid chromatography (HPLC)
methods have been developed for the quantification of RIF
and its metabolite 25ODESRIF, in plasma [8–10] and urinecorrespondence: saneesh.7.kumar@gmail.com
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ovided the original author and source are credited, a link to the[11–14]. These HPLC methods involve various procedures
which can be time-consuming. This is of critical importance
especially in assays involving HLMs and other liver fractions
(S9, hepatocytes), to identify the metabolites and also quantify
the rate of drug metabolism, as well as for major pharmacoki-
netic studies as well as herb–drug interaction (HDI) and drug–
drug interaction (DDI) studies. Metabolites may interfere with
the assay when analyzing parent drugs [15]. Rifampicin in-
duces the metabolism of many drugs, including antiretroviral
drugs (ARVs) such as nevirapine metabolized by the CYPs,
predominantly CYP3A4 and CYP2B6 [16, 17]. Few in vitro
studies have assessed Km and Vmax kinetic parameters of ri-
fampicin in human liver microsomes.
RIF-induced CYP3A4 activation and expression models
have been used for predicting the pharmacokinetics of
CYP3A4 substrate drugs as well as clinically relevant DDI
[18]. Most of the in vitro HDI studies have investigated the
role of RIF as an inducer of CYP3A4 along with other drugs
and herbal extracts; less information is available on the effect
of herbal medicines on the esterase-mediated metabolism path-
way of RIF to 25ODESRIF. Assessment of the metabolic dis-
position of RIF and of possible inhibitory/inducing effects of
herbal medicines would be very important.
Althaea officinalis L. (Malvaceae), commonly called “marsh-
mallow” (Baer-ul-Khtmk [African/Arabic]; Gulkhairo [Pers.]), is
a perennial species indigenous to Africa, which is used as an or-
namental plant and a medicinal plant by TB patients [19–21].Acta Chromatographica
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Evaluation of in vitro Metabolism of RifampicinThe present research describes an HPLC–PDA method for the
detection, separation, and quantitation of RIF and its principle
metabolite 25ODESRIF, which is robust with a shorter analysis
time and selective in the presence of first-line anti-TB drugs as
well as their metabolites. This study is also unique in the per-
spective of determining the kinetics of rifampicin (Km and Vmax)
based on the metabolite formation using HLM assays and is ap-
plied in investigating the HDI of RIF with the herbal extracts of
A. officinalis, by measuring the enzyme kinetics of 25ODESRIF.
Experimental
Materials and Reagents. Pure 25ODESRIF and NEO were
obtained from Clearsynth Labs Ltd. (Mumbai, India) while RIF
and nelfinavir mesylate hydrate (NELF) were obtained from
Sigma-Aldrich (Steinheim, Germany). HPLC-grade acetonitrile,
methanol, and ethanol were purchased from Sigma-Aldrich
(Steinheim, Germany) and ethyl acetate from BDH Chemicals
(England). High purity water was prepared by passage through a
Millipore system (Millipore, Billerica, MA, USA) and was used
as the mobile phase. The HLM screening was performed using
pooled human liver microsomes (mixed gender) from Xenotech
LLC, USA along with glucose-6-phosphate sodium salt, glucose-
6-phosphate dehydrogenase, magnesium chloride, phosphate
buffer solution of 1 M, and β-nicotinamide adenine dinucleotide
phosphate hydrate (NADPH) from Sigma-Aldrich (Steinheim,
Germany).
Preparation of Standards. The stock solutions for RIF,
25ODESRIF, and NEO were prepared at 4 mM concentrations,
in methanol, and the dilutions were made from the same with
diluents: a mixture of water and methanol in the ratio 50:50 v/v
spiked with the internal standard NEO (20 μM) [22, 23] for the
HPLC analysis. Dilutions were calculated from the stock solution
of RIF for all the pharmacokinetic assays. All solutions were
freshly prepared and filtered using 0.22 μ syringe filters, before
being subjected to HPLC analysis.
Plant Material and Extraction. The dried roots of A.
officinalis (Malvaceae) were obtained in packed form, from
Pharma Germania, Benoni, Gauteng (certificate of analysis no.
471255).
Four grams of the powdered roots were exhaustively
extracted with purified water after boiling and also with HPLC
grade methanol, ethanol, and ethyl acetate (made up to
500 mL for 9 days). The extract solutions were separately fil-
tered and evaporated at 50 °C using a concentrator–freeze drier
(miVac, England) to complete dryness to produce the aqueous
(yield: ±1166.54 mg, 29.16% w/w), methanol (yield:
±731.43 mg, 18.29% w/w), ethanol (yield: ±426.2, 10.66% w/w),Table 1. The HPLC-PDA parameters for separation method
Reference standard drug Rifampicin (RIF) 25-O-
Structure
Column Phenomenex Luna C-18 Column (150 × 4.6 mm, 5 μ)
Flow rate 0.8 mL/min
Run time 11.5 min
Injection 15 μL
Mobile phase (gradient) Water–methanol 90:10 (0 min)→ 20:80 (5 min)→ 5:9
Temperature 27 °C
Wavelength 254 nm
2and ethyl acetate extracts (yield: ±574.93 mg, 14.37% w/w) of
A. officinalis.
HPLC Instrumentation and Chromatographic Conditions.
The Waters Alliance 2695 Separations Module with 2996 PDA
Diode Array Detector HPLC System was used for method
development and validation. The output signal (254 nm) was
monitored and processed using QuickStart Empower Waters
2002 software. A Phenomenex Luna C-18 (150 × 4.6 mm, 5 μ)
column was used for the HPLC studies and method
development, as well as the pharmacological evaluation and the
HDI analysis, at column oven temperature of 27 °C.
Detection and Separation Method. Satisfactory separations
were achieved on the C-18 Phenomenex Luna column (150 ×
4.6 mm, 5 μ), by gradient elution using mobile phase
comprising of water (A)–methanol (B) at a flow of 0.8 mL/min.
The gradient solvent program was set as TTmin/%solution B at
0/10, 5/80, 10/95, 9/80, 11.5/10, and 12.5/10. The detection
wavelength was maintained at 254 nm (Table 1). All mobile
phases were filtered using 0.22 μ membrane solvent filters
(Merck Millipore, USA). The column oven temperature was
maintained at 27 °C, and the injection volume was 15 μL. A
post runtime of 2 min was maintained between each injection.
Method Validation. The method was validated for accuracy,
linearity, and precision. LLOD and LLOQ were determined based
on signal-to-noise ratio of 3 and 10, respectively, as per
International Conference on Harmonization (ICH) guidelines [24].
The signal-to-noise ratio was determined by comparing measured
signals from samples with known lowest concentrations of the
analyte with those of blank samples following two replicate
injections and establishing the minimum concentration at which
the analyte can be reliably detected or quantified.
In Vitro Evaluation of Rifampicin Kinetics. The method
was validated using HLM assay, by incubating RIF as the
substrate. Briefly, a standard 200 μL incubation mixture
containing liver microsomes (0.25 mg/mL protein concentration),
RIF (100 μM) in 0.2 M phosphate buffer, pH 7.4, at 37 °C was
incubated for 15, 30, 45, and 60 min, in duplicates. The
reactions were initiated with NADPH (final concentration
1.3 mM) along with the cofactors magnesium chloride (final
concentration 3.3 mM), glucose-6-phosphate (final concentration
1.3 mM), and glucose-6-phosphate dehydrogenase (1 U/mL) and
then terminated with 200 μL of chilled acetonitrile spiked with
the internal standard NEO (20 μM). The samples were
centrifuged using 0.22 μ polypropylene centrifuge tube filters
(Spine-XW Costar, USA) at 13,000 rpm for 5 min, and the
supernatants were subjected to HPLC analysis.
For determining the kinetics of RIF, various concentrations
in the range of 0–150 μM were incubated with HLM fordesacetyl rifampicin (25ODESRIF) Neostigmine methyl sulfate (NEO)
5 (10 min) → 90:10 (11.5–12.5 min)
Table 2. Regression statistics of RIF and 25ODESRIF
Parameters RIF 25ODESRIF
Linearity range (μM) 0–200 0–200
Correlation coefficient 0.9932 0.9976
Standard error 1.6181 2.1669
Intercept coefficient 16.9659 18.8773
LLOD (μM) 5.86 7.78
LLOQ (μM) 17.75 23.57
S. Kumar et al.30 min using the same procedure as above; the reactions were ter-
minated using 200 μL of chilled acetonitrile spiked with the inter-
nal standard and centrifuged, and the top layer of the supernatant
was subjected to HPLC analysis. The optimal incubation time
(30 min) and the concentration of HLM (0.25 mg/mL protein)
for the kinetics study was selected based on the rate of metabo-
lite formation from the time-variant incubations (Figure 3b).
Apparent kinetic constants (Km and Vmax) were estimated by fit-
ting formation rates of metabolite versus substrate concentra-
tions to the appropriate kinetic equations by nonlinear
regression analysis using GraphPad Software Inc. (San Diego,
CA; www.graphpad.com) Prism version 5.00 for Windows.
In Vitro Inhibition Screening Assays — HLM, Herbal
Extract, and Rifampicin. The method was applied for analyzing
herb–drug interactions of RIF with A. officinalis. The
inhibitory potential of the extracts (aqueous, methanol, ethanol,
and ethyl acetate) of A. officinalis was assessed using a two-
point screening with HLM, maintaining the final
concentrations of each extract at 20 and 200 μg/mL. Based on
the kinetic constant (Km) determined and the optimal
incubation conditions, 48 μM RIF was used as substrate to
determine the formation of 25ODESRIF, with 20 μM NEO as
the internal standard. Briefly, a standard 200 μL incubation
mixture containing HLM and substrate (0.25 mg/mL protein
concentration for 48 μM RIF) in 0.2 M phosphate buffer
(pH 7.4) and the plant extract (final concentration of 20 and
200 μg/mL, dissolved in <1% solvent) at 37 °C was incubated
for 30 min, in duplicates; the reactions were initiated using theFigure 1. HPLC chromatographic separation of RIF, 25ODESRIF, and NEO
lite, and internal standard
Figure 2. HPLC chromatographic separation of RIF, 25ODESRIF, and NEO
metabolite, 20 μM internal standardsame cofactor mix composition as described earlier. The
reactions were terminated using 200 μL of chilled acetonitrile
spiked with the internal standard and centrifuged, and the top
layer of the supernatant was analyzed using HPLC. NELF
(10 and 75 μM) was used as inhibitor control for the RIF
metabolic pathway, based on the assumption that certain CYP
inhibitors could also inhibit esterases [25].
The amount of 25ODESRIF formed relative to the control
was expressed in percentage remaining activity and calculated
as in equation below:
% residual activity ¼ test test controlð Þ
= control control blankð Þ  100%
Statistical analysis of the half inhibitory concentration (IC50)
was done based on to the two-point screening. The percentile of
residual activity was plotted against the log-transformed concen-
trations (of the herbal extract or the positive control). Non-linearusing the C-18 column at 4 mM concentrations of the drug, metabo-
using the C-18 column at 100 μM concentrations of the drug and its
3
Table 3. Robustness evaluation parameters and retention time of the
analytes for the HPLC method
Parameter Variation Retention time (min)
RIF 25ODESRIF NEO
Flow rate 0.6 mL/min 8.21 9.03 11.31
0.7 mL/min 7.91 8.53 10.98
0.8 mL/min 7.78 8.25 10.71
Temperature 27 °C 7.73 8.27 10.72
30 °C 7.74 8.25 10.75
34 °C 7.75 8.24 10.79
Wavelength 250 nm 7.75 8.28 10.68
254 nm 7.78 8.25 10.70
257 nm 7.79 8.26 10.69
Evaluation of in vitro Metabolism of Rifampicinregression analysis was done to obtain sigmoidal plots of enzyme
kinetic data for IC50, using GraphPad Software.
Results and Discussion
Development and Optimization of the HPLC Method.
The separation of the three analytes was not satisfactory when
using an isocratic method, especially due to interference fromFigure 3. a. HPLC chromatographic separation of RIF, 25ODESRIF, and NE
sample (75 μM RIF). b. Linearity graph for time variant incubations with R2
Figure 4. Kinetic analyses of RIF by human liver microsomes and formatio
4cofactors and secondary metabolites in the HLM assays; hence,
gradient elution was selected [26]. Method optimization was
done by different logical modifications such as change in
column length (100 mm, 150 mm, and 250 mm), inner
diameter (2.6 mm and 4.6 mm), particle size (3.5 μ and 5 μ),
and change in the elution gradient.
The separation of all three analytes was consistent and re-
producible in the C-18 Luna column and had a shorter run
time (Figures 1 and 2). The HPLC retention times were con-
sistent at ±7.70 min, ±8.25 min, and ±10.70 min for RIF,
25ODESRIF, and NEO, respectively, for the C-18 column.
The overall runtime per sample analysis was 11.5 min.
At millimolar concentrations of both drugs, the peaks were
more broadened and tailing, due to the retention affinity of
rifampicin and its metabolite to the column. The peak resolu-
tions were adequate in the concentration range relevant for
drug metabolism interaction studies (0–150 μM).
The C-18 Luna column provided good measurable separation
and consistent results for lower concentrations of both RIF and
25ODESRIF.O using the C-18 Luna column, for the in vitro HLM–RIF incubation
= 0.9901
n of 25ODESRIF versus RIF
Table 4. Kinetics of rifampicin metabolism
HLMs Km Vmax CLint
(Vmax/Km)
H0610, H0620, H0630, H0640
(Pooled HLM — Mixed, Xenotech)
48.23 1.233 0.026
Vmax, pmol/min/mg protein or pmol/min/pmol P450; Km, μM;
CLint, μL/min/mg protein or μL/min/pmol P450.
Figure 5. a. Two-point screening of the aqueous (AoAq), methanolic (AoMeOH)
against RIF metabolism pathway, with nelfinavir (NELF) as the positive cont
9.59 μM) against percentage remaining activity of rifampicin metabolism. c. H
the C-18 Luna column, for the in vitro HLM–RIF incubation samples (48 μM
incubate with 200 μg/mL aqueous extract of A. officinalis
S. Kumar et al.Method Validation
Linearity, LOD, and LOQ. A linear response was obtained
in the concentration range of 0–200 μM for both RIF and
25ODESRIF (R2 = 0.995). LLOD and LLOQ were calculated at
5.86 μM and 17.75 μM for RIF and 7.78 μM and 23.57 μM for
25ODESRIF, respectively. The results of the system suitability
tests assure the adequacy of the proposed HPLC method for, ethanolic (AoEtOH), and ethyl acetate (AoEtOAc) extracts of A. officinalis
rol. b. Statistical plot (IC50) of the positive control NELF (5.44 μg/mL,
PLC chromatographic separation of RIF, 25ODESRIF, and NEO using
RIF): A, test control (negative) incubate with no herb extract; B, assay
5
Evaluation of in vitro Metabolism of Rifampicinroutine analysis of RIF and 25ODESRIF alone or in combina-
tion. The regression statistics are as outlined in Table 2.
Statistically Designed Robustness Experiments. Robust an-
alytical methods using HPLC are required in quality control labo-
ratories for routine use, as well as in experiments involving HDI/
DDI studies. After finalizing the mobile phase composition and
column, statistically designed experiments were performed to
screen robustness of the analytical method and to select the ap-
propriate system suitability parameters (Table 3).
Specificity. The applicability of the validated HPLC method
for pharmacokinetic studies was tested using in vitro human liver
microsomal incubation assay. For all four time periods (15, 30,
45, and 60 min, in duplicates), the metabolite 25ODESRIF was
detected using this method at consistent retention times along
with RIF and NEO, and the peak area of NEO was relatively
constant (Figure 3a).
Linearity was established for the 15–60 min incubation range
based on the ratio of the metabolite to the internal standard, with
R2 = 0.99 (Figure 3b).
Kinetic Analyses of Rifampicin and Its Metabolite. The ki-
netics for the formation of 25ODESRIF from RIF was deter-
mined in several HLM incubations for concentrations in the
range of 0–150 μM. Representative Michaelis–Menten kinetic
plots from all assays are depicted in Figure 4, and the kinetic
parameters are summarized in Table 4.
Two-Point Screening of Herbal Extracts with Rifampicin.
The potential of the extracts of A. officinalis to inhibit the me-
tabolism pathway of RIF was investigated. The solvent ex-
tracts were screened at two concentrations (20 μg/mL and
200 μg/mL), and the observed remaining activity was
expressed as percentage of the negative control (no inhibitor).
For both enzymes, less than 1% solvent was used for the total
incubation, as per the assay standard guidelines; methanol
inhibited rifampicin metabolism by 20% at 2μL per 200μL in-
cubation concentration, while ethanol and ethyl acetate had no
effect on the enzyme activity.
None of the extracts of A. officinalis showed inhibition of
RIF metabolism at high and low concentrations (Figure 5a)
compared to NELF which inhibited the activity by about 30%
at 75 μM. NELF was further screened in the concentration
range of 1–100 μM, and it was observed that, at higher con-
centrations, it inhibited rifampicin metabolism in HLM and
had an IC50 value of 9.59 μM (5.44 μg/mL) (Figure 5b).
Conclusions
A specific, precise, and robust HPLC method was devel-
oped which could separate as well as accurately quantify RIF
and its major metabolite 25ODESRIF. The assay yielded well-
resolved peaks for RIF, 25ODESRIF, and NEO, with good ac-
curacy, precision, and recovery, within a short run time. The
suitability of the method for pharmacokinetic drug metabolism
studies was validated using HLM incubations, and the kinetics
of RIF were analyzed. The Km value expressed for the forma-
tion of 25ODESRIF in HLM was calculated to be 48.23 μM.
Previously reported values of rifampicin Km in transporters
SLCO1B1 (OATP1B1, OATP-C, OATP2, LST-1) in HeLa-
OATP1B1, OATP1B1-expressing oocytes, and SLCO1B3
(OATP1B3, OATP8) in OATP1B3-expressing oocytes were
1.5 μM, 13 μM, and 2.3 μM [27, 28], respectively.
In a study on Staphylococcus aureus, based on the accumulation
of 14C-rifampicin, the Km value expressed was 0.06 μM [29].
The in vitro data showed that 25ODESRIF is the primary
metabolite, which concurs with previous studies [30, 31]. Pos-
sible interactions of RIF with herbal medicines have been
reported previously [32–34]. However, not much research has
been done on the effect of herbal medicine on the metabolism6pathway of RIF to 25ODESRIF, which is critical because inhi-
bition of this metabolism pathway may result in toxicity, in-
cluding mortality [35, 36]. This HPLC method was
specifically used for analyzing the variations in the metabolic
profile of RIF, with or without various solvent extracts of A.
officinalis. The gradient elution provided clear separation of
the secondary plant metabolites from the major metabolite of
RIF and the internal standard with precision and consistency
(Figure 5c), and the amount of 25ODESRIF formed for each
assay was quantified relative to the negative control. A. officinalis
did not cause any inhibition of this pathway.
In conclusion, this HPLC–PDA analytical method is suit-
able for in vitro metabolism studies of RIF, including herb or
drug interaction studies.
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